跳至主要内容
临床试验/NCT01259609
NCT01259609已完成不适用

Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 82 人开始时间: 2008年9月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
82
试验地点
1
主要终点
ciliary body thickness

研究概览

简要总结

The purpose of this study is to determine whether ciliary body thickness increased in the presence of diabetic macular edema and whether it changed after pars plana vitrectomy.

详细描述

A diabetic macular edema group consisted of diabetic patients who underwent PPV for diffuse diabetic macular edema. A epiretinal membrane group, a surgical control group, consisted of non-diabetic patients with epiretinal membrane who underwent pars plana vitrectomy. A healthy control was also included for the comparison of preoperative ciliary body thickness. Ciliary body thickness was measured using ultrasound biomicroscopy, and central macular thickness was determined using optical coherence tomography. The visual outcome, ciliary body thickness, and central macular thickness were compared between groups before and 1, 2, and 4 months after pars plana vitrectomy and the correlations between the central macular thickness and ciliary body thickness and best corrected visual acuity were determined.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •for diabetic macular edema group:
  • •Diabetic macular edema with preoperative central macular thickness > 300 μm on optical coherence tomography
  • •Macular edema that was not associated with an epiretinal membrane or traction membrane
  • •No combined traction retinal detachment or vitreous hemorrhage
  • •No signs of ocular inflammatory disease on preoperative examination
  • •Phakic eye
  • •An axial length between 22.0 mm and 25.0 mm

排除标准

  • •for diabetic macular edema group:
  • •Patients with uveitis, inflammatory connective tissue disorders or a history of previous ocular surgery
  • •Long-term application of topical medication, a history of intravitreal steroid or anti-VEGF injection within 3 months before vitrectomy
  • •Inclusion Criteria for epiretinal membrane group:
  • •Non-diabetic patients with an epiretinal membrane who were scheduled for vitrectomy
  • •No ocular or systemic disease other than epiretinal membrane
  • •Inclusion Criteria for healthy group:
  • •No diabetes
  • •No ocular disease other than cataract

研究组 & 干预措施

Diabetic Macular Edema Group

Experimental

干预措施: Pars Plana Vitrectomy (Procedure)

Epiretinal Membrane Group

Active Comparator

干预措施: Pars Plana Vitrectomy (Procedure)

Healthy Control

No Intervention

结局指标

主要结局

ciliary body thickness

时间窗: up to four months after surgery

ciliary body thickness was determined using ultrasound biomicroscopy

次要结局

  • central macular thickness(up to four months after surgery)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验